Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Janux Therapeutics
Silicon Valley Bank’s Failure Rattles Investors In Biopharma Sector
Investment bank analysts, VC funds and biopharma companies all sought to calm investors’ nerves as a go-to financial institution for tech and biotech collapsed.
$1bn Amunix Buy Brings Sanofi Next-Generation TCE Platform
The deal bolsters Sanofi’s immuno-oncology pipeline and marks its sixth acquisition this year.
Finance Watch: Lyell Raises $425m As Eight Biopharmas Go Public In One Week
Public Company Edition: Eight drug developers launched initial public offerings in the US that grossed $1.46bn combined during the week of 14 to 18 June as biotechnology stock values increased. Also, C4 Therapeutics led recent follow-on offerings, raising $180.8m.
Finance Watch: Janux Offering Makes 47 Biopharma IPOs In 2021, So Far
Public Company Edition: The pace of US initial public offerings slowed a bit in April and May but could ramp back up in June as biopharma investor sentiment rebounds. Also, drug developers continue to go public via SPAC mergers, most recently Valo Health with a $2.8bn post-deal valuation.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.